Effects of Head and Extracranial Injuries on Serum Protein S100B Levels in Trauma Patients

Savola, Olli; Pyhtinen, J.; Leino, Tuomo; Siitonen, Simo; Niemelä, Onni; Hillbom, Matti

doi:10.1097/01.ta.0000096644.08735.72

Cited by 203 publications

(161 citation statements)

References 20 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…The initial S100 levels in patients with TBI (CCTq) were even slightly lower than those without TBI (CCT-). These biochemical observations have already been reported by other authors, who mostly used the Sangtec ᮋ 100 immunoassay on a LIA-mat ᮋ S100 analyzer (35,36). Extracerebral sources of S100 release into the systemic circulation obviously seem to play an important role in multiple trauma patients.…”

Section: Bereitgestellt Von | Universitaetsbibliothek Der Lmu Muenchensupporting

confidence: 55%

Significance of Elecsys® S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients

Mussack¹,

Kirchhoff²,

Buhmann³

et al. 2006

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: The neuroprotein S100 released into the circulation has been suggested as a reliable marker for primary brain damage. However, safe identification of relevant traumatic brain injury (TBI) may possibly be hampered by S100 release from peripheral tissue. The objective of this study was to measure early S100 levels using the Elecsys ᮋ S100 immunoassay for real-time assessment of severe TBI in multiple trauma. Methods: Consecutively admitted multiple trauma patients (injury severity score G16 points) were stratified according to the results of the initial cerebral computed tomography (CCT) examination. S100 serum levels were determined at admission and at 6, 12, 24, 48 and 72 h after trauma. Data were correlated to creatine phosphokinase (CK) and lactate dehydrogenase (LDH) serum levels. Using receiver operating characteristic (ROC) analysis, the discriminating power of S100 measurement was calculated for the detection of CCTq findings. Results: Median S100 levels of CCTq patients (ns9;

show abstract

Section: Bereitgestellt Von | Universitaetsbibliothek Der Lmu Muenchensupporting

confidence: 55%

Significance of Elecsys® S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients

Mussack¹,

Kirchhoff²,

Buhmann³

et al. 2006

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…This has raised concerns as to whether the serum levels of this protein actually correlate with the degree of brain damage or are more reflective of blood brain barrier (BBB) disruption. Secondly, S100B has been reported to be released into the serum after experimental ischemic injury to the liver, kidney, and gut; 16 its levels have been found to have increased after extracranial trauma 14 and burns, 17 and it has been suggested to be a biomarker of melanoma. 18 Finally, conflicting reports have been published regarding the usefulness of this marker in predicting outcome after pediatric TBI.…”

Section: S100bmentioning

confidence: 99%

“…Similar to that observed at higher injury magnitudes, the serum concentration of this marker is transiently increased after MTBI. 14 For example, a clinical study evaluating serum S100B levels in patients with mild head injuries found that patients with intracranial injuries (as determined by using head CT scans) had significant elevations in S100B levels compared with patients who did not have such injuries. 95 Consistent with this evaluation, a recent re-evaluation of six prospective clinical trials involving more than 2000 MTBI patients indicated that S100B has a sensitivity of 98.2% in identifying the presence of brain injury.…”

Section: Biomarkers For Mild Tbimentioning

confidence: 99%

Biomarkers for the Diagnosis, Prognosis, and Evaluation of Treatment Efficacy for Traumatic Brain Injury

et al. 2010

View full text Add to dashboard Cite

“…It has been shown that injury other than head trauma can be the cause of increased S-100β levels. 23 Anderson and colleagues have demonstrated that S-100β levels can be increased up to 40 times as a consequence of soft tissue trauma and increased by two orders of magnitude after bone fractures. 24 In order to exclude extracranial injury as confounding factor in our study, we excluded 49 of the originally recruited patients because of significant additional trauma other than head injury, most commonly fractures of the extremities (n =14), serial rib fractures (n = 11) and pneumothorax (n = 6).…”

Section: Methodsmentioning

confidence: 99%

Can Admission S-100β Predict the Extent of Brain Damage in Head Trauma Patients?

Schültke

Sadanand²,

Kelly³

et al. 2009

Can. j. neurol. sci.

View full text Add to dashboard Cite

612S-100β, a small monomer of the calcium-binding S-100 protein family, is present in high concentrations in astrocytes and Schwann cells. S-100β levels in serum were initially identified as a valuable marker in the assessment of cerebral injury during cardiovascular surgery and stroke. [1][2][3][4] Over the last decade, several groups have published their results correlating S-100β levels in serum to the severity of brain damage and patient outcome. Positive correlation of S-100β levels with computerized tomography (CT) and magnetic resonance imaging (MRI) findings were documented. [5][6][7][8][9][10] In patients who had suffered mild head trauma, S-100β levels in serum were found to be a specific but not very sensitive predictor for postconcussion symptoms 11 , while no correlation was found between S-100β serum levels and cognitive performance in the early stage of recovery. 12 S-100β serum levels were found to be a ABSTRACT: Background: As has been shown previously, S-100β levels in serum can be a useful predictor of brain damage after head trauma. This pilot study was designed to investigate whether urine samples, which are much easier to obtain, could be used for the same purpose instead of serum samples. Methods: Ninety-six consecutive patients admitted with head trauma were recruited in the study. After exclusion of 54 patients, mostly because of significant additional trauma, S-100β levels were analyzed in serum and urine of 42 patients using a luminometric assay. A range for normal values was established based on samples from ten healthy volunteers. Results: S-100β serum levels increased proportional to the severity of the head trauma, as had been previously shown by several other groups. In many patients, initial increases in urine S-100β levels were seen later than in serum, after which the kinetics of S-100β levels in urine seemed to follow that established for serum levels. S-100β values in urine were on average about 54% lower in urine than in serum. Conclusions: S-100β levels in urine obtained on admission to the hospital are not a good indicator for the extent of brain damage. However, urine S-100β levels obtained at later time points might be a useful indicator for the development of secondary brain injury. RÉSUMÉ: Le niveau de S-100β au moment de l'admission peut-il prédire l'étendue du dommage cérébral chez les traumatisés crâniens?Contexte : Tel que démontré antérieurement, les niveaux sériques de S-100β peuvent être utiles pour prédire le dommage cérébral après un traumatisme crânien. Cette étude pilote a été conçue afin d'étudier si des échantillons d'urine, qui sont beaucoup plus faciles à obtenir, pourraient être utilisés à cet effet plutôt que des échantillons de sérum. Méthodes : Quatre-vingt-seize patients consécutifs admis pour traumatisme crânien ont été inclus dans l'étude. Cinquante-quatre patients ont été exclus de l'étude, la plupart du temps à cause de la présence d'autres traumatismes importants. Les niveaux de S-100β ont été mesurés dans le sérum et l'urine de 42 patients au ...

show abstract

Effects of Head and Extracranial Injuries on Serum Protein S100B Levels in Trauma Patients

Cited by 203 publications

References 20 publications

Significance of Elecsys® S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients

Significance of Elecsys® S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients

Biomarkers for the Diagnosis, Prognosis, and Evaluation of Treatment Efficacy for Traumatic Brain Injury

Can Admission S-100β Predict the Extent of Brain Damage in Head Trauma Patients?

Contact Info

Product

Resources

About